

IMAGINE-II Manual of Operations

Table of Contents

IMAGINE-II STUDY

LUM001-305

A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME

Developed in Collaboration with ChiLDRen



CHAPTER 1 STUDY ORGANIZATION AND RESPONSIBILITIES

1.1 Background

1.2 Study Roles and Responsibilities

- 1.2.1 Shire
- 1.2.2 Premier Research
- 1.2.3 ERT
- 1.2.4 CRL
- 1.2.5 Specialty Laboratories
- 1.2.6 Quotient Clinical (Quotient)
- 1.2.7 The ChiLDRen Data Coordinating Center
- 1.2.8 The ChiLDRen Clinical Sites
- 1.2.9 Data Safety Monitoring Board (ChiLDRen DSMB)

1.3 Chapter References

- 1.3.1 Sponsor, Collaborator, and Vendor Address Information

- 1.3.2 LUM001-305 IMAGINE II Site Numbering Convention
- 1.3.3 Investigational New Drug (IND) Memo
- 1.3.4 Health Canada Approval Letter
- 1.3.5 IMAGINE II may proceed letter
- 1.3.6 IMAGINE II sponsorship letter

CHAPTER 2 STUDY ADMINISTRATION

2.1 Study Personnel

2.2 Pre-Study Documentation Required

2.3 Study Start-Up Process

2.4 Study Documentation and Storage

2.5 Chapter References

- 2.5.1 Site Contact and Shipment Information Form
- 2.5.2 Lumena Regulatory Documents Guidelines (USA)
- 2.5.3 Statement of Investigator (1572 Form)
- 2.5.4 Certification/Disclosure Form (Financial Disclosure by Clinical Investigator)
- 2.5.5 Investigator Site File Index
- 2.5.6 Protocol Signature Page
- 2.5.7 Investigator Brochure Signature Page
- 2.5.8 Investigator Acknowledgement of Receipt

CHAPTER 3 STUDY ROSTER

3.1 Description

3.2 Chapter References

- 3.2.1 Study Directory
- 3.2.2 ChiLDRen DSMB Roster (found in the DSMB report)

CHAPTER 4 STUDY OVERVIEW

4.1 Background and Rationale

4.2 Objectives

4.3 Investigational Plan

4.4 Efficacy Evaluations

4.5 Chapter References

- 4.5.1 IMAGINE-II Study Clinical Protocol Number LUM001-305
Protocol Amendment 5: 13 November 2017
- 4.5.2 Protocol Notes to File

CHAPTER 5 SCREENING AND RECRUITMENT

5.1 Population

5.2 Screening and Recruitment Plan

5.3 Eligibility

- 5.3.1 Inclusion Criteria
- 5.3.2 Exclusion Criteria
- 5.3.3 Protocol Amendment 5 Inclusion and Exclusion Criteria: Eligible subjects for the long-term optional follow-up treatment period

5.4 Master Subject Screening/Enrollment Log

5.5 Chapter References

- 5.5.1 Master Subject/ Screening/Enrollment Log
- 5.5.2 Confidential Subject Identification List LUM001-305
- 5.5.3 IMAGINE Banner Eunice

CHAPTER 6 INFORMED CONSENT

6.1 Informed Consent Document

6.2 Obtaining Informed Consent

6.3 Re-Consent

6.4 Clinical Trial Liability Insurance

6.5 Health Insurance Portability & Accountability Act (HIPPA) Compliance

6.6 Chapter References

- 6.6.1 Informed Consent Assent Log LUM001-305
- 6.6.2 IMAGINE II Study Clinical Protocol Number LUM001-305
Protocol Amendment 5: 13 November 2017
- 6.6.3 Lumena Memo Re: Clinical Trial Liability Insurance
- 6.6.4 Consent to Take Part in a Research Study (Parental)
- 6.6.5 Consent to Take Part in a Research Study (Subject Age 18)
- 6.6.6 Documentation of Assent from Pediatric Subjects (Recommended for Ages 7-11)

- 6.6.7 Documentation of Assent from Pediatric Subject (Recommended for Ages 12-17)
- 6.6.8 Re-initiation Consent to Take Part in a Research Study (Parental)
- 6.6.9 Re-initiation Consent to Take Part in a Research Study (Subject Age 18)
- 6.6.10 Re-initiation Documentation of Assent from Pediatric Subjects (Recommended for Ages 7-11)
- 6.6.11 Re-initiation Documentation of Assent from Pediatric Subject (Recommended for Ages 12-17)
- 6.6.12 PA5 Dose Escalation Consent to Take Part in a Research Study (Parental)
- 6.6.13 PA5 Dose Escalation Consent to Take Part in a Research Study (Subject Age 18)
- 6.6.14 PA5 Dose Escalation Assent from Pediatric Subjects (Recommended for Ages 7-11)
- 6.6.15 PA5 Dose Escalation Assent from Pediatric Subjects (Recommended for Ages 12-17)

CHAPTER 7 STUDY DRUG

7.1 Preparation and Dispensing

7.2 Dose Escalation Period

7.3 Dose Optimization Period

7.4 Stable Dosing and Safety Monitoring Periods

7.5 Long-term Optional Follow-up Treatment Period

7.6 Dose Escalation following Dose Interruptions

7.7 Concomitant Medications

7.8 Chapter References

- 7.8.1 Master Study Drug Accountability Log
- 7.8.2 Individual Subject Study Drug Accountability Log
- 7.8.3 Subject Diary Booklet for Study Drug
 - 7.8.3.1 IMAGINE II Diary Booklet Week 1
 - 7.8.3.2 IMAGINE II Diary Booklet Week 2
 - 7.8.3.3 IMAGINE II Diary Booklet Week 3
 - 7.8.3.4 IMAGINE II Diary Booklet Week 4
 - 7.8.3.5 IMAGINE II Diary Booklet Week 5
 - 7.8.3.6 IMAGINE II Diary Booklet Week 6
 - 7.8.3.7 IMAGINE II Diary Booklet Week 7
 - 7.8.3.8 IMAGINE II Diary Booklet Week 8

- 7.8.3.9 IMAGINE II Diary Booklet Week 9
- 7.8.3.10 IMAGINE II Diary Booklet Week 10
- 7.8.3.11 IMAGINE II Diary Booklet Week 11
- 7.8.3.12 IMAGINE II Diary Booklet Week 12
- 7.8.3.13 IMAGINE II Diary Booklet Week 13-24
- 7.8.3.14 IMAGINE II Diary Booklet Week 25-36
- 7.8.3.15 IMAGINE II Diary Booklet Week 37-44
- 7.8.3.16 IMAGINE II Diary Booklet Week 45-48
- 7.8.3.17 IMAGINE II Diary Booklet Week 49-60
- 7.8.3.18 IMAGINE II Diary Booklet Week 61-72
- 7.8.3.19 IMAGINE II Diary Booklet Week 73-84
- 7.8.3.20 IMAGINE II Diary Booklet Week 85-96
- 7.8.3.21 IMAGINE II Diary Booklet Week 97-108
- 7.8.3.22 IMAGINE II Diary Booklet Week 109-120
- 7.8.3.23 IMAGINE II Diary Booklet Week 121-132
- 7.8.3.24 IMAGINE II Diary Booklet Week 133-144

7.9 Investigator Brochure

CHAPTER 8 STUDY PROCEDURES

8.1 Schedule of Procedures

8.2 Study Visits

- 8.2.1 Baseline (Day 0)
- 8.2.2 Week 1 Phone Contact (Day 7 \pm 2)
- 8.2.3 Week 2 Clinic Visit (Day 14 \pm 2)
- 8.2.4 Week 3 Phone Contact (Day 21 \pm 2)
- 8.2.5 Week 4 Clinic Visit (Day 28 \pm 2)
- 8.2.6 Week 6 Phone Contact (Day 42 \pm 5)
- 8.2.7 Week 8 Clinic Visit (Day 56 \pm 5)
- 8.2.8 Week 10 Phone Contact (Day 70 \pm 5)
- 8.2.9 Week 12 Clinic Visit (Day 84 \pm 5)
- 8.2.10 Week 16 Clinic/Phone Visit (Day 112 \pm 14)
- 8.2.11 Week 20 Phone Contact (Day 140 \pm 14)
- 8.2.12 Week 24 Clinic Visit (Day 168 \pm 14)
- 8.2.13 Week 28 Phone Contact (Day 196 \pm 14)
- 8.2.14 Week 32 Phone Contact (Day 224 \pm 14)
- 8.2.15 Week 36 Clinic Visit (Day 252 \pm 14)
- 8.2.16 Week 40 Phone Contact (Day 280 \pm 14)
- 8.2.17 Week 44 Clinic Visit (Day 308 \pm 14)
- 8.2.18 Week 48 Clinic Visit (Day 336 \pm 14)
- 8.2.19 Week 52 Phone Contact (Day 364 \pm 14)
- 8.2.20 Week 56 Phone Contact (Day 392 \pm 14)
- 8.2.21 Week 60 Clinic Visit (Day 420 \pm 14)
- 8.2.22 Week 64 Phone Contact (Day 448 \pm 14)

- 8.2.23 Week 68 Phone Contact (Day 476 \pm 14)
- 8.2.24 Week 72 Clinic Visit (Day 504 \pm 14)
- 8.2.25 Week 76 Phone Contact (Day 532 \pm 14)
- 8.2.26 Week 80 Phone Contact (Day 560 \pm 14)
- 8.2.27 Week 84 Clinic Visit (Day 588 \pm 14)
- 8.2.28 Week 88 Phone Contact (Day 616 \pm 14)
- 8.2.29 Week 92 Phone Contact (Day 644 \pm 14)
- 8.2.30 Week 96 or Early Termination Clinic Visit (Day 672 \pm 14)
- 8.2.31 Week 100 Phone Contact (Day 700 \pm 14)
- 8.2.32 Week 104 Phone Contact (Day 728 \pm 14)
- 8.2.33 Week 108 Clinic Visit (Day 756 \pm 14)
- 8.2.34 Week 112 Phone Contact (Day 784 \pm 14)
- 8.2.35 Week 116 Phone Contact (Day 812 \pm 14)
- 8.2.36 Week 120 Clinic Visit (Day 840 \pm 14)
- 8.2.37 Week 124 Phone Contact (Day 868 \pm 14)
- 8.2.38 Week 128 Phone Contact (Day 896 \pm 14)
- 8.2.39 Week 132 Clinic Visit (Day 924 \pm 14)
- 8.2.40 Week 136 Phone Contact (Day 952 \pm 14)
- 8.2.41 Week 140 Phone Contact (Day 980 \pm 14)
- 8.2.42 Week 144 EOT/ET Clinic, Visit (Day 1008 \pm 14)
- 8.2.43 Week 148 EOS Clinic Visit (\pm 5)

8.3 Unscheduled Visits

8.4 Study Instruments

8.5 Data Entry and Source Documentation

8.6 Chapter References

- 8.6.1 Study Visits
 - 8.6.1.1 Study Visit Worksheets
 - 8.6.1.2 LUM001-305 Telephone Visit Contact Guide
 - 8.6.1.3 Lumena 305 Quotient Form Submission Guide
 - 8.6.1.4 LUM001-305 Study Blank CRF Casebook
 - 8.6.1.5 Electronic Case Report Form (eCRF) Completion Guide
- 8.6.2 Laboratory
 - 8.6.2.1 Lab Manual
 - 8.6.2.2 ITCH Collection Lab Processing
 - 8.6.2.3 IMAGINE II Estimated Minimum/Maximum blood/urine volumes by visit
 - 8.6.2.4 LUM001-305 Lab Sample Priority
- 8.6.3 Caregiver ItchRO/Patient ItchRO
 - 8.6.3.1 IMAGINE II eDiary PT Training Guide
 - 8.6.3.2 IMAGINE II Quick Start Training Guide
 - 8.6.3.3 IMAGINE II Help Desk Sticker
 - 8.6.3.4 LUM001-305 eDiary Cheat Sheets

- 8.6.4 IMAGINE II Pruritis Assessments
 - 8.6.4.1 Clinician Scratch Score
 - 8.6.4.2 Clinician Xanthoma Assessment
 - 8.6.4.3 Caregiver Impression of Change
- 8.6.5 Quality of Life Assessment (Peds QL)
 - 8.6.5.1 Pediatric Quality of Life Inventory
 - 8.6.5.2 Multidimensional Fatigue Scale
 - 8.6.5.3 Family Impact Module
- 8.6.6 DataLabs
 - 8.6.6.1 eCRF guidelines
 - 8.6.6.2 Data pro training manual
 - 8.6.6.3 System Requirements
 - 8.6.6.4 elearning registration letter
- 8.6.7 Pharmacy
 - 8.6.7.1 Dosing and Study Drug Administration Guidelines Document
 - 8.6.7.2 Form A - Notification of Subject Entering Extension
 - 8.6.7.3 Form B - Baseline/Day 0 Weight
 - 8.6.7.4 Form C - Dose Optimization Form
 - 8.6.7.5 Form D - Subject Withdrawal
 - 8.6.7.6 Form W - 10% Weight Change Notification
 - 8.6.7.7 Form F – Notification of “Roll-Over” Subject from Stable Dosing Period to Safety Monitoring Period
 - 8.6.7.8 Form G – Notice of Re-Initiation Following Dosing Interruption>7 days
 - 8.6.7.9 Form J – Notification of “Roll-Over” Subject from PA4 to PA5
 - 8.6.7.10 Central Pharmacy FAQ’s
- 8.6.8 LUM001-305 Pregnancy Data Collection Form
- 8.6.9 Spanish Translated Documents/Certificates
- 8.6.10 Frequently Asked Questions (FAQ’s)

CHAPTER 9 ADVERSE EVENT (AE) / SERIOUS ADVERSE EVENT (SAE) / REGULATORY REPORTING

9.1 Definitions

- 9.1.1 Adverse Event
- 9.1.2 Adverse Reaction and Suspected Adverse Reaction
- 9.1.3 Serious Adverse Event (SAE)
- 9.1.4 Non-Serious Adverse Events
- 9.1.5 Evaluation of Adverse Events (Serious and Non-Serious)

9.2 Procedures for Handling Special Situations

- 9.2.1 Intolerance to Study Drug
- 9.2.2 Pregnancy Reporting
- 9.2.3 Abnormalities of Laboratory Tests

9.2.4 Medical Monitoring & Pharmacovigilance Contact Information

9.3 Chapter References

9.3.1 SAE Reporting and Flow

9.3.2 LUM001-305 SAE Form

9.3.3 Data and Safety Monitoring Plan 27-FEB-2016

9.3.4 IMAGINE-II Study Clinical Protocol Number LUM001-305
Protocol Amendment 5: 13 November 2017

- Emergency Contact Information (Page 5)
- Product Quality Complaints (Page 6)

CHAPTER 10 DATALABS ELECTRONIC DATA CAPTURE (PREMIER)

CHAPTER 11 STUDY MANAGEMENT AND MONITORING

11.1 Study Monitoring – On Site Monitoring

11.2 Site Initiation Visit

11.2.1 Meeting with Principal Investigator (PI), Sub-Investigators (*Sub-I*),
Study Coordinators (*SC*), Pharmacy Staff (*Pharm.*), and Laboratory
Staff (*Lab*):

11.2.2 Conduct Facility Tour

11.3 Interim Monitoring Frequency

11.4 Routine Monitoring Visits

11.5 Site Close-Out Visit

11.6 Communication

11.7 Chapter References

11.7.1 Site Personnel Training Log

11.7.2 Delegation of Authority Log

11.7.3 Monitor Visit Log

11.7.4 Site Initiation Visit Confirmation Letter

11.7.5 Site Personnel Confirmation of GCP Training